Abstract：
UNASSIGNED: Osteoarthritis (OA) related pain has affected millions of people worldwide. However, the current pharmacological options for managing OA-related pain have not achieved a satisfactory effect.
UNASSIGNED: This narrative review provides an overview of the current and emerging drugs for OA-related pain. It covers the drugs\' mechanism of action, safety, efficacy, and limitations. The National Library of Medicine (PubMed) database was primarily searched from 2000 to 2024.
UNASSIGNED: Current treatment options are limited and suboptimal for OA pain management. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are the recognized and first-line treatment in the management of OA-related pain, and other drugs are inconsistent recommendations by guidelines. Emerging treatment options are promising for OA-related pain, including nerve growth factor (NGF) inhibitors, ion channel inhibitors, and calcitonin gene-related peptide (CGRP) antagonists. Besides, drugs repurposing from antidepressants and antiepileptic analgesics are shedding light on the management of OA-related pain. The management of OA-related pain is challenging as pain is heterogeneous and subjective. A more comprehensive strategy combined with non-pharmacological therapy needs to be considered, and tailored management options to individualized patients.
UNASSIGNED: This narrative review provides an overview of the current and emerging drugs for OA-related pain. It covers the drugs\' mechanism of action, safety, efficacy, and limitations. The National Library of Medicine (PubMed) database was primarily searched from 2000 to 2024.
UNASSIGNED: Current treatment options are limited and suboptimal for OA pain management. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are the recognized and first-line treatment in the management of OA-related pain, and other drugs are inconsistent recommendations by guidelines. Emerging treatment options are promising for OA-related pain, including nerve growth factor (NGF) inhibitors, ion channel inhibitors, and calcitonin gene-related peptide (CGRP) antagonists. Besides, drugs repurposing from antidepressants and antiepileptic analgesics are shedding light on the management of OA-related pain. The management of OA-related pain is challenging as pain is heterogeneous and subjective. A more comprehensive strategy combined with non-pharmacological therapy needs to be considered, and tailored management options to individualized patients.
摘要：
■骨关节炎（OA）相关的疼痛已影响到全球数百万人。然而,目前治疗OA相关疼痛的药物选择尚未取得令人满意的效果.
■这篇叙述性综述概述了当前和新兴的OA相关疼痛药物。它涵盖了药物的作用机制，安全,功效,和限制。国家医学图书馆（PubMed）数据库的主要检索时间为2000年至2024年。
■目前的治疗选择是有限的，对于OA疼痛管理来说并不理想。外用非甾体抗炎药（NSAIDs）是公认的治疗OA相关疼痛的一线治疗方法，和其他药物的指南建议不一致。新兴的治疗方案对OA相关疼痛很有希望，包括神经生长因子（NGF）抑制剂，离子通道抑制剂，和降钙素基因相关肽（CGRP）拮抗剂。此外,从抗抑郁药和抗癫痫镇痛药中重新利用的药物正在为OA相关疼痛的治疗提供启示.OA相关疼痛的管理是具有挑战性的，因为疼痛是异质性和主观性的。需要考虑与非药物治疗相结合的更全面的策略，并为个性化患者量身定制管理选项。
■这篇叙述性综述概述了当前和新兴的OA相关疼痛药物。它涵盖了药物的作用机制，安全,功效,和限制。国家医学图书馆（PubMed）数据库的主要检索时间为2000年至2024年。
■目前的治疗选择是有限的，对于OA疼痛管理来说并不理想。外用非甾体抗炎药（NSAIDs）是公认的治疗OA相关疼痛的一线治疗方法，和其他药物的指南建议不一致。新兴的治疗方案对OA相关疼痛很有希望，包括神经生长因子（NGF）抑制剂，离子通道抑制剂，和降钙素基因相关肽（CGRP）拮抗剂。此外,从抗抑郁药和抗癫痫镇痛药中重新利用的药物正在为OA相关疼痛的治疗提供启示.OA相关疼痛的管理是具有挑战性的，因为疼痛是异质性和主观性的。需要考虑与非药物治疗相结合的更全面的策略，并为个性化患者量身定制管理选项。
